Arthneeti
Latest: Solara Active Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
SA

Solara Active

Q1 FY27Pharmaceuticals & Biotechnology

Solara Active Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹632
Market cap₹2.9K Cr
P/E690.5
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

The company targets a sustainable revenue growth of around 10% year-on-year for the base business (Page 14-15). The company expects around 10% year-on-year growth in the base business revenues, considered sustainable in the near term.

From Solara Active's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • The company targets a sustainable revenue growth of around 10% year-on-year for the base business (Page 14-15).
  • Recent quarters show a new plateau with base business revenues crossing INR 300 crores, indicating a higher level of operations (Page 9).
  • Year-on-year growth for Q1 FY27 over Q1 FY26 was approximately 24%, and even after adjusting for pass-through cost inflation, growth was around 18-19% (Page 9).

2 more points from Solara Active's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Solara Active said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • For FY '27, Solara has committed to close to INR 55-60 crores of capex.
  • Around INR 40 crores of this is towards incremental debottlenecking capex to increase capacity for high-margin products.
  • The remaining INR 10-15 crores is for maintenance capex, including plant upgrades and equipment replacements.
  • Similar capex levels of INR 40-50 crores per year are planned for FY '28 and FY '29.
  • Greenfield capex is currently not being actively considered, although the company remains open to opportunities as they evolve.

2 more points from Solara Active's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Solara Active said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
Relevant insights include: - The company is focusing on expanding its existing base business and seeding new businesses. - The base business has shown strong momentum with revenues up 24% year-on-year. - There is ongoing geographic expansion and new business wins. - The company is actively manufacturing and selling around 40-50 products from a basket of 50-60 products.

2 more points from Solara Active's call on order book

Create a free account to keep reading this call

Solara Active — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹417 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Solara Active and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Solara Active Q1 FY27 results?

The company targets a sustainable revenue growth of around 10% year-on-year for the base business (Page 14-15). The company expects around 10% year-on-year growth in the base business revenues, considered sustainable in the near term.

What is Solara Active share price analysis?

Solara Active currently shows a below-average growth signal. The stock trades at a P/E of 690.5 with a market cap of ₹2,948 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active planning capital expenditure?

For FY '27, Solara has committed to close to INR 55-60 crores of capex.

Keep Solara Active on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.